California’s Kite strikes deals with Fosun and Daiichi Sankyo.
Biotech plans pivotal trial next year.
Kite to start filing data for KTE-C19 with US regulator.
Backed by Amgen, Kite outlines bold plan for developing CAR-T and TCR cells.
Biggest ever CAR-T study in
Novartis may have concerns about commercial prospects, says expert.
Swiss pharma axes gene therapy unit, causing investor angst.